Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Biol Ther. 2013 Feb;14(2):95-9. doi: 10.4161/cbt.22960. Epub 2012 Nov 28.

A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.

Author information

1
Knight Cancer Institute and Department of Dermatology, Oregon Health and Science University, Portland, OR, USA. kuleszma@ohsu.edu and ryanc@ ohsu.edu

Abstract

Current therapies for Renal Cell Carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulation of VEGF. A subset of patients harbor primary-refractory disease, as in this case, where there was no evidence for loss of VHL or chromosome 3p. We evaluated molecular targeted agents in viable tumor cells cultured from a patient's clear cell renal cell carcinoma (RCC). Of 66 agents, only dasatinib, an inhibitor of Src tyrosine kinase, strongly reduced viability of the patient's cultured kidney tumor cells. Immunostaining of the original primary tumor revealed strong positivity for VHL and Src protein expression. Functional evaluation of a patient's tumor cells appears feasible in the setting of RCC.

KEYWORDS:

molecular targeted therapy; renal cell carcinoma; tyrosine kinase

PMID:
23192268
PMCID:
PMC3572006
DOI:
10.4161/cbt.22960
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center